Praxis (NASDAQ: PRAX) counsel adds 78 ESPP shares, holds 26,010.667

Rhea-AI Filing Summary

Praxis Precision Medicines General Counsel and Secretary Alex Nemiroff reported an acquisition of company stock through an employee plan. On this Form 4, Nemiroff received 78 shares of Praxis Precision Medicines common stock at a price of $167.943 per share.

These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). After this award, Nemiroff directly holds a total of 26,010.667 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nemiroff Alex

Role General Counsel and Secretary

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	78	$167.943	$13K

Holdings After Transaction: Common Stock — 26,010.667 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 78 shares Reported price per share: $167.943 per share Total holdings after transaction: 26,010.667 shares +1 more

4 metrics

Shares acquired 78 shares Common stock acquired on Form 4

Reported price per share $167.943 per share Price for the 78 acquired shares

Total holdings after transaction 26,010.667 shares Direct common stock ownership after acquisition

Transaction type Grant/award acquisition Code A, exempt under Rule 16b-3(c) and (d)

Key Terms

Employee Stock Purchase Plan, Rule 16b-3(d), Rule 16b-3(c), Grant, award, or other acquisition

4 terms

Employee Stock Purchase Plan financial

"These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt..."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3(d) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

Rule 16b-3(c) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nemiroff Alex

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A(1)		78	A	$167.943	26,010.667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Alex Nemiroff	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PRAX General Counsel Alex Nemiroff report?

Alex Nemiroff reported acquiring 78 shares of Praxis Precision Medicines common stock. The shares were obtained through the company’s Employee Stock Purchase Plan as a compensation-related transaction, not an open-market purchase, and are part of his overall equity position in PRAX.

At what price were the newly acquired PRAX shares recorded on the Form 4?

The 78 Praxis Precision Medicines shares were recorded at $167.943 per share. This figure reflects the transaction price reported in the Form 4 and is tied to the acquisition under the Employee Stock Purchase Plan rather than a standard market trade.

How many PRAX shares does Alex Nemiroff hold after this reported transaction?

Following this acquisition, Alex Nemiroff directly holds 26,010.667 shares of Praxis Precision Medicines common stock. This total includes the 78 shares received under the Employee Stock Purchase Plan and represents his reported direct ownership after the transaction.

Was the PRAX insider share acquisition an open-market purchase or a plan transaction?

The acquisition was a plan transaction, not an open-market purchase. The Form 4 states the 78 shares were acquired under the Praxis Precision Medicines Employee Stock Purchase Plan and designated as a grant, award, or other acquisition exempt under Rule 16b-3 provisions.

What does Rule 16b-3 exemption mean for this PRAX insider transaction?

The filing notes the transaction was exempt under Rule 16b-3(d) and Rule 16b-3(c). These exemptions generally apply to issuer-approved employee or director compensation plans, indicating this acquisition is treated as a routine equity compensation-related event rather than a discretionary market trade.